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Penile growth is under androgenic control. Human chorionic gonadotropin (hCG) has 
a stimulatory effect on testicular steroidogenesis and penile growth. The purpose of 
this study was to evaluate the effect of hCG treatment on the gonadal response and 
penile growth in male idiopathic hypogonadotrophic hypogonadism (IHH) presenting 
with micropenis. A total of 20 IHH patients who met the criteria for micropenis were 
included in this study. hCG (1,500-2,000 IU) was administrated intramuscularly, 3 
times per week, for 8 weeks. Basic laboratory and hormonal indexes (including serum 
testosterone and LH levels), penis length (flaccid and stretched), and testicular volume 
were measured before and 24 weeks after hCG treatment. The patients’ mean age was 
18.9 years (range, 12 to 24 years). The mean serum testosterone level was significantly 
increased after hCG treatment (baseline, 2, 4, 12, and 24 weeks: 0.90±1.35 ng/ml, 1.77±
1.31 ng/ml, 3.74±2.24 ng/ml, 5.49±1.70 ng/ml, and 5.58±1.75 ng/ml, respectively; p＜
0.05). Mean penile length also increased significantly 24 weeks after treatment (flaccid 
length: from 3.39±1.03 cm to 5.14±1.39 cm; stretched length: from 5.41±1.43 cm to 7.45±
1.70 cm; p＜0.001). Mean testicular volumes increased significantly as well (left: from 
5.45 cc to 6.83 cc; right: from 5.53 cc to 7.03 cc). There were no remarkable adverse effects 
of the hCG treatment. The hCG treatment increased the serum testosterone level, pen-
ile length, and testicular volume in IHH patients. Our results suggest that hCG treat-
ment has a beneficial effect on gonadal function and penile growth in patients with IHH 
presenting with micropenis.
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　Idiopathic hypogonadotrophic hypogonadism (IHH) is 
associated with deficient pituitary gonadotropin secretion 
due to impaired secretion of GnRH from the hypothalamus. 
The deficiency may be isolated or may occur in conjunction 
with other disorders.
1 Men with IHH present clinically with 
delayed sexual maturation and may have associated mid-
line defects such as Kallman’s syndrome.
1 The main goal 
of treatment in adolescent or young men is to restore serum 
androgen to normal levels by hormonal application such as 
testosterone or human chorionic gonadotropin (hCG), thus 
allowing virilization, penile growth, and puberty to be ac-
complished, and finally, inducing fertility when appropriate. 
Normal testosterone levels may be achieved with exoge-
nous testosterone administration. Alternatively, endoge-
nous testosterone secretion can be stimulated by using 
hCG.
2 Penile growth is under androgenic control, but hCG 
also has a stimulatory effect on testicular steroidogenesis 
and penile growth. One study reported that the final tes-
ticular volume in patients with IHH treated with hCG was 
substantially greater than that in patients treated with 
testosterone.
3
　Micropenis refers to an extremely small penis with a 40
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TABLE 1. The basal characteristics of the patients before hCG 
treatment
Variables Value (Mean±SD)
Number of patients 20












SD: standard deviation, *Mean penile length: circumcised length
(From Hwang IS, Study on penile length of Korean young adults.
Korean J Urol 2005;46:621-5).
FIG. 1. Change in the mean serum testosterone level after hCG 
treatment. *: p＜0.05 vs baseline.
stretched penile length of less than 2.5 SD below the mean 
for age or stage of sexual development.
4 Micropenis is one 
of the presenting symptoms of IHH; however, few studies 
have evaluated the response to hCG therapy in adolescent 
or adult men with IHH in terms of micropenis. The purpose 
of this study was therefore to determine the effect of hCG 
therapy on the gonadal response and penile growth in men 
with IHH who presented with micropenis.
MATERIALS AND METHODS
1. Patients
　A total of 20 male patients with IHH who met the criteria 
for micropenis were included in this study. The results were 
analyzed retrospectively by chart review and were approved 
by an institutional review board and ethics committee. 
Patients with cryptorchidism or its absence according to 
the imaging studies conducted at the initial presentation 
were excluded. The hCG stimulation test was performed 
in all patients to exclude primary testicular insufficiency. 
Additionally, all men had normal basal thyroid and adre-
nal function. A pituitary mass lesion or a suprasellar tumor 
was excluded by skull X-ray and by cranial computed tomo-
graphy. 
2. Diagnosis of IHH
　The diagnosis of IHH was made on the basis of low or nor-
mal serum LH and FSH concentrations associated with low 
serum testosterone, otherwise normal anterior pituitary 
function, and no demonstrable lesion on a high-resolution 
CT scan or MRI of the hypothalamic-pituitary area.
3. Methods
　1) Clinical and laboratory assessment: Testis volume was 
assessed by using the Prader orchidometer. Gonadotrophin 
(LH, FSH) levels were measured by immunoradiometric 
assays. Serum testosterone was measured following orga-
nic solvent extraction by radioimmunoassay. Basic labo-
ratory and endocrine assessments were performed (inclu-
ding serum testosterone, LH, and FSH levels) and penis 
length (flaccid and stretched) and testicular volume were 
measured before and after hCG treatment. 
　2) Hormonal therapy: The patients were treated by using 
a standard protocol of 1,500 IU to 2,000 IU hCG adminis-
trated intramuscularly, 3 times per week, for 8 weeks. 
　3) Penile length measurement: Penile length was meas-
ured by one doctor (K. Park). A wooden spatula was pressed 
against the pubic ramus depressing the suprapubic pad of 
fat as completely as possible to ensure that the part of the 
penis that is buried in the subcutaneous fat was measured. 
Measurement was made along the dorsum of the penis to 
the tip of the glans penis. The length of foreskin was not 
included.
4. Statistical analysis
　The data are given as the mean±SD unless otherwise 
indicated. Comparisons of data within a patient were eval-
uated by Student’s t test; comparisons of data from diffe-
rent subsets were evaluated by unpaired t test. Multiple 
means were compared by ANOVA.  
RESULTS
　The clinical features of the patients are shown in Table 
1. The patients’ mean age was 18.9 years (range, 12 to 24 
years). The mean testicular volume of the patients was less 
than 6 ml (measured by Prader orchidometer) at the time 
of assessment. The basal serum LH (mIU/ml), FSH (mIU/ 
ml), and prolactin (ng/ml) levels were 0.72±0.53 (reference 
range, 1.3-13.0), 0.23±0.14 (reference range, 0.9-15.0), and 
11.39±1.75 (reference range, 2.0-15.0), respectively (Table 
1). There were no remarkable adverse events related to the 
hCG treatment.
1. Increase in serum testosterone after hCG treatment
　The mean serum testosterone level was significantly in-41
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TABLE 2. Testosterone levels, penile length, and testis volume be-
fore and after hCG treatment
Variables Baseline  24 weeks  p value 
Serum testosterone (ng/dL) 0.90±1.35 5.58±1.75 ＜0.001
Penile length (cm)
　Flaccid 3.39±1.03 5.14±1.43 ＜0.001
　Stretched 5.14±1.95 7.45±1.70
Testis volume (mL)
　Left 5.45±0.78 6.83±0.54 ＜0.001
　Right 5.53±0.49 7.03±0.71
creased after hCG treatment. The serum testosterone levels 
at baseline and after 2, 4, 12, and 24 weeks of hCG treatment 
were 0.90±1.35 ng/ml, 1.77±1.31 ng/ml, 3.74±2.24 ng/ml, 
5.49±1.70 ng/ml, and 5.58±1.75 ng/ml, respectively (p＜ 
0.05) (Fig. 1).
2. Increase in penile length after hCG treatment
　Penile length was measured with the penis flaccid and 
fully stretched. The mean penile length also increased sig-
nificantly after hCG treatment. The flaccid and stretched 
length after hCG treatment increased from 3.39±1.03 cm 
to 5.14±1.39 cm and from 5.41±1.43 cm to 7.45±1.70 cm, re-
spectively (p＜0.001) (Table 2). 
3. Increase in testicular volume after hCG treatment
　The mean testicular volume measured by orchidometer 
increased significantly as well after hCG treatment. Testis 
volume increased from 5.45 cc to 6.83 cc on the left side and 
from 5.53 cc to 7.03 cc on the right side (p＜0.005) (Table 2).
DISCUSSION
　In this study, patients with isolated IHH had a good res-
ponse to hCG therapy in terms of penile growth, testicular 
growth, and elevation of serum testosterone. Although the 
present study included relatively severe cases whose initial 
mean testicular volume was less than 6 mL, the majority 
of patients achieved a good response. The hCG treatment 
increased serum concentrations of testosterone, testicular 
volume, and penile length. Therefore, our results suggest 
that patients with IHH will have a good response to hCG 
therapy in terms of testicular growth, improvement in serum 
testosterone, and increased penile growth, even patients 
with severe forms of hypogonadotropic hypogonadism.
　IHH is a congenital disorder with deficient pituitary go-
nadal secretion that may occur in conjunction with other 
disorders.
1 The central defect in most men with IHH is the 
loss of pulsatile secretion of GnRH from the hypothalamus.
5-8 
The objectives of therapy in adolescent and young adult 
males are to restore normal serum androgen levels to induce 
penile growth and puberty, and finally, to induce fertility. 
Although penile growth is dependent on androgenic con-
trol, hCG is also known to have a stimulatory effect on testi-
cular steroidogenesis and penile growth. 
　Micropenis, a presenting symptom of IHH, refers to an 
extremely small penis with a stretched penile length of less 
than 2.5 SD below the mean for age or stage of sexual devel-
opment.
4 The most important concern in a patient with mi-
cropenis is whether the patient will have sufficient penile 
growth to allow sexual function as an adult. It is well known 
that micropenis results from a lack of adequate androgen 
action during early fetal life that hinders full masculiniza-
tion of the external genitalia and induces inadequate an-
drogen stimulation for normal penile growth. Among the 
suggested etiologic factors of micropenis, the most common 
cause of micropenis is failure of the hypothalamus to se-
crete gonadotropins or hypophysial dysfunction.
9 When 
treating patients with anterior pituitary or hypothalamic 
dysfunction, hCG can be used to induce puberty instead of 
testosterone, which has the additional advantage of pro-
ducing testicular enlargement and initiating spermato-
genesis.
10 Few studies, however, have evaluated penile 
growth in response to hCG therapy in adolescent patients 
with IHH. In cases of idiopathic IHH combined with micro-
penis, hCG alone has been reported to increase penile 
length.
2 In the current study, we studied the effect of hCG 
therapy on the gonadal response and penile growth in male 
patients with IHH presenting with micropenis. Our results 
show that hCG treatment can successfully improve penile 
length in IHH patients. 
　Normal testosterone levels may be achieved with exoge-
nous testosterone administration. Alternatively, endoge-
nous testosterone secretion can be stimulated by using 
hCG. Additionally, the final testicular volumes in patients 
with IHH treated with hCG are substantially greater than 
in patients treated with testosterone.
3 Previously, many 
other studies reported a good response to gonadotropin 
therapy in males with IHH. Schopohl et al
11 reported that 
gonadotropin therapy with 3×2,500 IU hCG as a weekly in-
tramuscular injection restored endocrine and exocrine tes-
ticular function to the normal range in male patients with 
IHH. They showed that the serum level of testosterone, 
positive sperm count, and testicular volume were increased 
significantly in the gonadotropin-injected group. Burris et 
al
12 investigated the effect of exogenous hCG alone in IHH 
men in terms of serum testosterone, spermatogenesis, and 
testicular growth. They reported that hCG treatment in-
creased the testicular volume from 5.5 (pretreatment) to 
10.8 mL (maximum) during treatment and that all men at-
tained normal serum testosterone levels after hCG treat-
ment. During hCG treatment, 14 of the 22 men had positive 
sperm appearance in their semen. Ley and Leonard
13 also 
reported that hCG treatment is sufficient to both initiate 
and maintain spermatogenesis. Although the studies men-
tioned above reported the effect of gonadotropin therapy in 
males with IHH, all studied heterogeneous groups of males 
with complete or partial gonadotropin deficiency, which 
may be one reason for the good response to the hCG treat-
ment. 
　The spectrum of gonadotropin deficiency is manifested 
by the men’s initial testis volume.
14 The initial testicular 42
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volume of men with IHH is highly correlated with maximum 
testicular volume and sperm production.
12 A testicular vol-
ume of less than 4 mL is considered to indicate complete 
gonadotropin deficiency, whereas a testicular volume of at 
least 4 mL is considered to indicate some degree of gonado-
tropin stimulation.
15,16 In this study, we included patients 
with mean testicular volumes less than 6 mL at the initial 
diagnosis, and the patients showed a good response to hCG 
therapy. Therefore, we suggest that hCG treatment may 
have a beneficial effect on gonadal function in patients with 
a small testicular volume and on penile growth in patients 
presenting with micropenis. 
　A limitation of our study is that we could not measure se-
men parameters before and after surgery, because most of 
our patients were of an adolescent age and did not agree 
to provide a semen sample. Another limitation is the small 
sample size and the absence of a control group treated with 
combined human menopausal gonadotropin (hMG) or tes-
tosterone. The appropriate timing and dosage of hCG the-
rapy and its mode of action has not been conclusively de-
termined, and controversy currently exists in the literature. 
Furthermore, our study population was mixed with both 
adolescent and adult patients, and we could not evaluate 
the outcomes separately for these different age groups of 
prepubertal and postpubertal patients. It is uncertain whe-
ther the initial gain in penile length will be maintained into 
adulthood. Further study is needed with a prospective de-
sign, large sample size, long-term follow-up in terms of pe-
nile growth, and a control group of patients with another 
treatment modality.
　In conclusion, hCG treatment seemed to be effective in 
IHH, because it successfully increased the serum testoster-
one level and testicular volume and stimulated penile 
growth. Our data also imply that hCG treatment for pa-
tients with IHH presenting with micropenis results in a 
satisfactory gain in penile length.
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